Biotech Values

[DewDiligence]

Re: MNTA / M118 results in PCI

There was never any real doubt that M118 would work as well as heparin in this indication; the only question was whether some bizarre safety problem would turn up, although this was unlikely inasmuch as M118 is derived from heparin.

Now that M118 has succeeded in showing comparable safety and efficacy to heparin in PCI, MNTA can ink a partnership deal and the partner can proceed to a phase-2b trial in ACS.